Genprex, Inc.

Analysis for Ticker: GNPX

Genprex Inc is a clinical-stage business focused on creating gene therapies to treat cancer and diabetes. The company is currently operating under a terminal financial warning, with auditors stating there is significant doubt it can stay in business after losing a total of 171$ million. The current share price sits at approximately 0,93$ and the total market value of the entire entity has collapsed to just 8,56$ million. While the treasury is nearly empty, the people running the company have proactively raised their own salaries and granted themselves free stock, even as the Nasdaq exchange has placed them under a lethal one-year monitor that will trigger an instant delisting if their equity falls below 2,5$ million. The math is a disaster because the company must keep selling its own shares to survive, even though there is almost no value left for the people who own them.